Prediction of miRNA‑mRNA network regulating the migration ability of cytarabine‑resistant HL60 cells
- Authors:
- Published online on: December 13, 2023 https://doi.org/10.3892/br.2023.1708
- Article Number: 20
-
Copyright: © Hsu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
Acute myeloid leukemia (AML) cells arise from hematopoietic stem cells (HSCs) or myeloid progenitors in which key driver mutations have occurred (1). A subpopulation of leukemic cells within the malignant population, known as leukemia stem cells (LSCs), is considered to have self-renewing stem cell properties and are capable of initiating disease when engrafted into an immunocompromised host (2). The standard therapeutic approach for AML is cytarabine-based therapy that starts with induction chemotherapy [continuous infusion of cytarabine for 7 days concurrent with short infusions of anthracycline on each of the first 3 days (7+3 regimen)], followed by several cycles of consolidation chemotherapy or allogeneic HSC transplantation (3,4). However, only ~70% of patients receiving standard induction therapy achieve complete remission, and only 40% become long-term survivors (3,5). Older patients with AML exhibit stronger intrinsic resistance and less tolerance to chemotherapy than younger patients, resulting in a poor response to standard induction therapy (6). Intensive therapy with high-dose cytarabine improves the overall survival rate and reduces AML recurrence; however, the risk of drug-related side effects is also increased. AML treatment in older patients has not improved significantly in recent decades compared with that in younger patients (7). A more thorough understanding of the drug resistance mechanisms is required to provide effective cancer treatments and improve outcomes.
Cytarabine is a pyrimidine analog and converts into the triphosphate form within the cell. Cytarabine then incorporates into DNA strands during the S phase of the cell cycle to inhibit DNA synthesis (8). Insufficient cellular uptake and retention of cytarabine, overexpression of enzymes that inactivate cytarabine, increased cellular deoxycytidine triphosphate (dCTP) pool, and increased DNA repair are the main mechanisms of cytarabine resistance (7). Overall, the reduced expression of human equilibrating nucleoside transporter 1 (hENT1) and deoxycytidine kinase (dCK) play pivotal roles during the development of cytarabine resistance in leukemia cells (7). However, other new mechanisms associated with cytarabine resistance have been discovered consecutively. In 2017, Farge et al reported that AML cells have increased oxidative phosphorylation after cytarabine treatment, and inhibition of oxidative phosphorylation could restore sensitivity to cytarabine (9). High-dose cytarabine-based therapy causes a decrease of the cytidine diphosphate pool that may accelerate the reduction of dCTP, thereby obstructing DNA synthesis. In addition, high-dose cytarabine treatment increases the AMP/ATP ratio that can trigger AMP-activated protein kinase and subsequently forkhead box class O, thereby promoting cell cycle arrest (10). However, therapeutic strategies to overcome cytarabine resistance have not been developed. A comprehensive understanding of the mechanisms underlying cytarabine resistance is necessary to optimize cytarabine therapy.
MicroRNAs (miRNAs or miRs) are highly-conserved single-stranded noncoding RNAs of ~22 nucleotides (11). In most cases, miRNAs induce mRNA degradation and translational repression by complementary binding to the 3'-untranslated region of the target mRNA (12). Although miRNAs do not participate in transcription and translation, they modify and control processes including cell division, self-renewal, invasion and DNA damage (13). MiRNA expression is known to be dysregulated in human cancers (14,15). Dysregulated miRNA expression by several mechanisms, such as copy number alterations, epigenetic changes, location of miRNA near oncogenomic regions and aberrant targeting of miRNA promoter regions, contribute AML pathogenesis (16). However, chemotherapy for AML often involves a combination of drugs that complicates research; thus, the role of miRNAs in drug resistance has not been thoroughly investigated. The role of miRNAs in leukemogenesis is unquestionable and miRNAs may prove to be an important addition to treatment of drug-resistant cancers in the future (17). Before specific miRNAs can be integrated into modern cancer therapies, clearly elucidating their mechanisms is necessary.
The present study provided comprehensive findings on differentially expressed miRNAs (DEMs) and differentially expressed genes (DEGs) during the development of cytarabine resistance in HL60 cells, revealing new opportunities for refractory or cytarabine-resistant AML.
Materials and methods
Cell culture
The R-HL60 cell line was established through the continuous treatment of parental HL60 cells (ATCC) with increasing concentrations of cytarabine as previously described (4). Both HL60 and R-HL60 cells were maintained in RPMI-1640 medium (Cytiva) containing 10% fetal bovine serum and 1% antibiotic-antimycotic solution (both from Gibco; Thermo Fisher Scientific, Inc.) under a humidified atmosphere of 5% CO2 at 37˚C.
RNA isolation
Total RNA from HL60 and R-HL60 cells was extracted using TRIzol Reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. The RNA samples were submitted to Welgene Biotech. Co., Ltd. for small RNA sequencing and gene expression array analysis. RNA quantity was determined using an ND-1000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc.) and RNA quality was verified using an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.).
Small RNA sequencing
MiRNA sequencing libraries were prepared using the QIAseq miRNA Library Kit (cat. no. 331502; Qiagen GmbH) according to the manufacturer's protocol, and were sequenced using the NextSeq 500/550 High Output Kit (75 cycles; cat. no. FC-404-2005; Illumina, Inc.). The loading concentration of the final library was 1.6 pM, measured by High Sensitivity D1000 ScreenTape assay (High Sensitivity D1000 ScreenTape, cat. no. 5067-5584; and High Sensitivity D1000 Reagents, cat. no. 5067-5585; Agilent Technologies, Inc.). The type of sequencing setup was 75-bp single end. Sequencing data was processed using the Illumina software program BCL2FASTQ v2.20.0.422 (https://support.illumina.com/sequencing/sequencing_software/bcl2fastq-conversion-software/downloads.html). Subsequently, the Trimmomatic v0.36 program (http://www.usadellab.org/cms/?page=trimmomatic) was implemented to filter poor quality reads and trim poor quality bases on the basis of the quality score. Qualified reads after filtering low-quality data were analyzed using miRDeep2 v0.05 software (https://github.com/rajewsky-lab/mirdeep2) and were aligned to the reference genome downloaded from the University of California Santa Cruz (UCSC) Genome Browser (https://hgdownload.soe.ucsc.edu/downloads.html). miRNAs were mapped to few genomic locations; therefore, only reads that mapped perfectly to the genome with a ≤5-fold difference were used for miRNA identification.
Gene expression array
A Low Input Quick Amp Labeling Kit (cat. no. 5190-2305; Agilent Technologies, Inc.) was used to amplify 200 ng of total RNA and fluorescent Cy3 dye (included in the labeling kit; Agilent Technologies, Inc.) was used to label RNA oligonucleotides. A total of 600 ng Cy3-labeled cRNA was fragmented to an average size of 50-100 nucleotides by incubation with fragmentation buffer at 60˚C for 30 min. Correspondingly fragmented labeled cRNAs were pooled and hybridized to the SurePrint Microarray (Agilent Technologies, Inc.) at 65˚C for 17 h. The Cy3 microarray was scanned at 535 nm with an Agilent microarray scanner, and the scans were analyzed using Feature Extraction 10.7.3.1 software (Agilent Technologies, Inc.).
MiRNA-mRNA network analysis
The DEGs and DEMs with a fold change of ≥2 during the development of cytarabine resistance in HL60 cells were selected. The miRNA target genes were predicted using three online databases: miRDB, TargetScan, and miRTarBase (18-20). The miRNA-mRNA pairs with negative correlation were screened out on the basis of the hypothesis that miRNA negatively regulates the target mRNA. The miRNA-mRNA network was constructed by using Cytoscape 3.8.2 software (21).
Functional enrichment analysis
Gene ontology (GO) analysis was performed using ShinyGO 0.76 to determine the biological functions of the DEGs included in the candidate miRNA-mRNA network (22,23). Protein-protein interaction analysis in the cluster associated with the regulation of cell migration, locomotion, cellular component movement, cell motility, and localization was performed using STRING 11.5(24).
Transwell migration assay
A Transwell chamber consisting of an upper and a lower chamber separated by a porous membrane was used for the cell migration assay. Cells were suspended in serum-free RPMI-1640 medium and plated in the upper chamber with 8-µm pores (Guangzhou Jet Biofiltration Co., Ltd.), adjusting the cell concentration to 2.5x105 cells/ml. RPMI-1640 medium with 10% fetal bovine serum was added to the lower chamber. The Transwell chamber was incubated in an incubator with 5% CO2 at 37˚C, and then the cells in the lower chamber were collected and counted by Cell Counting Kit-8 (CCK-8) assay (Energenesis Biomedical Co., Ltd.) after incubating for 24 and 48 h. In detail, a 200-µl volume obtained from the lower chamber was transferred to a 96-well plate, then 20 µl CCK-8 solution was added per well and incubation followed for 2 h. Subsequently, the specific absorbance and reference absorbance of each well were measured at 450 and 650 nm, respectively, by an enzyme-linked immunosorbent assay reader (Epoch2; Agilent Technologies, Inc.).
Statistical analysis
Data were analyzed using GraphPad Prism 5.0 (GraphPad Software Inc.; Dotmatics). A Student's paired t-test was used to determine the differences between the experimental and control groups. Data are representative of three independent experiments, with values presented as the mean ± standard deviation and P<0.05 was considered to indicate a statistically significant difference.
Results
DEGs and DEMs between HL60 and R-HL60 cells
To investigate the alterations of miRNA and mRNA profiles during the development of cytarabine resistance in HL60 cells, miRNA and mRNA profiles of HL60 and R-HL60 cells were determined using small RNA sequencing and gene expression array analysis, respectively. The flowchart of candidate miRNA-mRNA target pair selections and subsequent functional enrichment analysis is displayed in Fig. 1. The standard setting for identifying DEMs was >1 read per million (RPM). DEMs and DEGs, with an adjusted P-value <0.05 were considered statistically significant and selected for further investigation. In the present study, the experimental design of previous studies was referred to and DEMs and DEGs whose expression changes between HL60 and R-HL60 cells were ≥2-fold were selected for analysis (25,26). Small RNA sequencing data revealed that there were 75 DEMs with a ≥2-fold difference between HL60 and R-HL60 cells, of which 34 DEMs had higher expression levels in R-HL60 than those in parental HL60 cells, and 41 DEMs had lower expression levels in R-HL60 than those in parental HL60 cells. Gene expression array data showed that there were 274 DEGs with a ≥2-fold difference between R-HL60 and HL60 cells, of which 185 DEGs had higher expression levels in R-HL60 than those in parental HL60 cells, and 89 DEGs had lower expression levels in R-HL60 than those in parental HL60 cells. Negatively associated miRNA-mRNA pairs predicted using the miRDB, Targetscan, or miRTar database were selected as candidate miRNA-mRNA target pairs. Candidate miRNA-mRNA target pairs including 17 DEMs (5 upregulated miRNAs and 12 downregulated miRNAs) and 28 DEGs (19 upregulated genes and 9 downregulated genes) are presented in Table I. Heat maps revealing the hierarchical clustering of 17 DEMs and 28 DEGs are shown in Fig. 2, and the candidate miRNA-mRNA network was visualized using Cytoscape 3.8.2 software (Fig. 3).
Functional enrichment analysis of DEGs
Functional enrichment analysis was performed for 28 DEGs included in the candidate miRNA-mRNA target pairs. The histogram of the top 20 most-enriched GO pathways is displayed in Fig. 4A, and genes involved in the GO pathways are listed in Table II. The hierarchical clustering tree revealed the relationships between similar sets of data (Fig. 4B). In addition, 10 genes (CCL2, SOX9, SLC8A1, ICAM1, CXCL10, SIPR2, FGFR1, OVOL2, MITF and CARD10) were simultaneously involved in seven GO terms related to the regulation of migration ability, namely ‘regulation of cell migration’, ‘regulation of locomotion’, ‘regulation of cellular component movement’, ‘cell migration’, ‘locomotion’, ‘cell motility’, and ‘localization of cell’. The modulation of migration ability is considered as a possible therapeutic target in refractory AML (27), therefore, the present study focused on analyzing the candidate miRNA-mRNA pairs associated with the modulation of migration ability. The candidate miRNA-mRNA pairs involved in these GO terms associated with the regulation of migration ability are listed in Table III. Among them, SIPR2 was not present in the STRING database; therefore, protein-protein interaction analysis was performed for the remaining nine genes in the cluster (Fig. 4C). In addition, the interactive graph displays the percentage of shared gene members for the enriched GO terms (Fig. 4D).
 | Table IITop 20 most-enriched GO pathways involved in the development of cytarabine resistance in HL60 cells. |
| Table IIIIntegration of miRNA-mRNA pairs involved in the regulation of cell migration behavior or ability during the development of cytarabine resistance in HL60 cells. |
Comparison of migration ability between HL60 and R-HL60
Transwell migration assays were used to compare the migration ability of HL60 and R-HL60 cells. The results showed that the migration ability of R-HL60 cells was ~2-folds higher than that of parental HL60 cells following incubation for 24 h, and was ~3-folds higher than that of parental HL60 cells following incubation for 48 h (Fig. 5).
Discussion
Cytarabine is the main drug used for AML treatment, however, drug resistance hinders the achievement of complete remission. Although miRNAs are known to be often dysregulated in AML, the role of miRNAs in the development of drug resistance has not been thoroughly investigated. The present study, to the best of the authors' knowledge, is the first to comprehensively compare the integrated miRNA-mRNA network between HL60 and R-HL60 cells, and reveal that 16 miRNA-mRNA pairs, including miR-1-3p/CCL2, miR-1-3p/SOX9, miR-1-3p/SLC8A1, miR-155-5p/CCL2, miR-155-5p/ICAM1, miR-1255b-5p/ICAM1, miR-200c-5p/CXCL10, miR-3609/CXCL10, miR-1285-3p/SIPR2, miR-1285-3p/CXCL10, miR-124-3p/FGFR1, miR-124-3p/OVOL2, miR-124-3p/MITF, miR-146a-5p/CARD10, miR-497a-5p/CARD10, and miR-3150a-3p/CARD10, participate in the regulation of migration ability during the development of cytarabine resistance in HL60 cells (Table III). Among them, miR-1-3p targeting CCL2 (28); miR-1-3p targeting SOX9 (29); miR-1-3p targeting SLC8A1 (30); and miR-146-5p targeting CARD10 (31) have been confirmed by luciferase assay in previous studies. In addition, miR-1-3p (32), miR-1255-5p (33), miR-200c-5p (34), miR-155-5p (35), miR-1285-3p (36), miR-124-3p (37) and miR-146a-5p (38,39) have been also reported to regulate cell migratory behavior in several cell models.
Several studies have reported associations between miRNAs and AML outcomes. For example, patients with high expression levels of miR-126-5p/3p had poor survival. Transfection of the mimic miR-126-5p into an AML cell line (KG-1) resulted in decreased sensitivity to cytarabine (40). A specific anti-miR-21 oligonucleotide (AMO-miR-21) inhibited cell viability and induced apoptosis in HL60 cells. AMO-miR-21 in combination with cytarabine enhanced the sensitivity to cytarabine and promoted cytarabine-induced apoptosis. These effects of AMO-miR-21 may be partially due to upregulated PDCD4, a direct target of miR-21(41). In addition, miRNA-181a overexpressed in AML cells downregulated the expression of ataxia telangiectasia mutated (ATM), a DNA damage response protein. Thus, DNA damage could not be repaired by ATM, leading to uncontrolled growth and drug resistance in AML cells (42). However, it is considered that comparing drug-resistant cells with parental cells would reveal the actual mechanisms of drug resistance more effectively than studying chemotherapy sensitivity on parental cells alone.
Unlike solid cancers, which gradually acquire motility, leukemia has inherent cell motility ability as leukocytes that move throughout the vascular system. The precise location of leukemia origin is often unknown, which has led to controversy about whether leukemia should be considered a metastatic disease (1). Even so, widespread organotropic dissemination is a common feature of liquid and solid cancers. It was revealed that high-dose cytarabine treatment inhibited the migratory ability of the C1498 AML cell line and that of the MLL-AF9 oncogene-induced AML mouse model (27,43). However, proliferative C1498 cells could restore migratory ability after relapse (27). Although the association between migration ability and chemotherapy resistance is complex and not yet clarified, modulation of migration ability is considered as a possible therapeutic target in refractory AML (27).
The lack of validation in other drug-resistant cell lines and clinical specimens is a limitation of the present study. However, the study revealed the possible mechanisms underlying the regulation of cell migration ability during the development of cytarabine resistance in HL60 cells. This may assist in the development of targeted therapies for modulating cell migration in refractory AML.
Acknowledgements
Not applicable.
Funding
Funding: The present study was supported by the National Science and Technology Council of Taiwan (grant no. MOST 109-2314-B-037-103-MY3 and NSTC 112-2314-B-037-063) and the Kaohsiung Medical University Hospital (Kaohsiung, Taiwan) (grant nos. KMUH109-9R49, KMUH110-0R45 and KMUH111-1R42).
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. The sequencing datasets generated and/or analyzed during the current study are available in the Gene Expression Omnibus repository (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE221719).
Authors' contributions
WYH, SSC and YHT conceived and designed the experiments. PCL, YML and CYY performed the experiments and data analysis. CYY and YHT confirm the authenticity of all the raw data. WYH wrote the manuscript. YHT edited the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
References
|
Whiteley AE, Price TT, Cantelli G and Sipkins DA: Leukaemia: A model metastatic disease. Nat Rev Cancer. 21:461–475. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Vetrie D, Helgason GV and Copland M: The leukaemia stem cell: Similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 20:158–173. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Dombret H and Gardin C: An update of current treatments for adult acute myeloid leukemia. Blood. 127:53–61. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Tseng YH, Chiou SS, Weng JP and Lin PC: Curcumin and tetrahydrocurcumin induce cell death in Ara-C-resistant acute myeloid leukemia. Phytother Res. 33:1199–1207. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Tseng YH, Yang RC, Chiou SS, Shieh TM, Shih YH and Lin PC: Curcumin induces apoptosis by inhibiting BCAT1 expression and mTOR signaling in cytarabine-resistant myeloid leukemia cells. Mol Med Rep. 24(565)2021.PubMed/NCBI View Article : Google Scholar | |
|
Yanada M and Naoe T: Acute myeloid leukemia in older adults. Int J Hematol. 96:186–193. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Wang SY, Shih YH, Shieh TM and Tseng YH: Proteasome inhibitors interrupt the activation of Non-Canonical NF-κB signaling pathway and induce cell apoptosis in Cytarabine-Resistant HL60 cells. Int J Mol Sci. 23(361)2021.PubMed/NCBI View Article : Google Scholar | |
|
Bhise NS, Chauhan L, Shin M, Cao X, Pounds S, Lamba V and Lamba JK: MicroRNA-mRNA pairs associated with outcome in AML: From in vitro Cell-Based studies to AML patients. Front Pharmacol. 6(324)2015.PubMed/NCBI View Article : Google Scholar | |
|
Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, et al: Chemotherapy-Resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 7:716–735. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Li Z, Guo JR, Chen QQ, Wang CY, Zhang WJ, Yao MC and Zhang W: Exploring the antitumor mechanism of high-dose cytarabine through the metabolic perturbations of ribonucleotide and deoxyribonucleotide in human promyelocytic Leukemia HL-60 Cells. Molecules. 22(499)2017.PubMed/NCBI View Article : Google Scholar | |
|
Yen MC, Yeh IJ, Liu KT, Jian SF, Lin CJ, Tsai MJ and Kuo PL: Next-generation sequencing predicts interaction network between miRNA and target genes in lipoteichoic acid-stimulated human neutrophils. Int J Mol Med. 44:1436–1446. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Liu Y, Cheng Z, Pang Y, Cui L, Qian T, Quan L, Zhao H, Shi J, Ke X and Fu L: Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia. J Hematol Oncol. 12(51)2019.PubMed/NCBI View Article : Google Scholar | |
|
Zhang J, Gu Y and Chen B: Mechanisms of drug resistance in acute myeloid leukemia. Onco Targets Ther. 12:1937–1945. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Yu DS, Song XL and Yan C: Oncogenic miRNA-1908 targets HDAC10 and promotes the aggressive phenotype of cervical cancer cell. Kaohsiung J Med Sci. 37:402–410. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Ali Syeda Z, Langden SSS, Munkhzul C, Lee M and Song SJ: Regulatory mechanism of MicroRNA expression in cancer. Int J Mol Sci. 21(1723)2020.PubMed/NCBI View Article : Google Scholar | |
|
Trino S, Lamorte D, Caivano A, Laurenzana I, Tagliaferri D, Falco G, Del Vecchio L, Musto P and De Luca L: MicroRNAs as new biomarkers for diagnosis and prognosis, and as potential therapeutic targets in acute myeloid leukemia. Int J Mol Sci. 19(460)2018.PubMed/NCBI View Article : Google Scholar | |
|
Gabra MM and Salmena L: microRNAs and acute myeloid leukemia chemoresistance: A mechanistic overview. Front Oncol. 7(255)2017.PubMed/NCBI View Article : Google Scholar | |
|
Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, Huang WC, Sun TH, Tu SJ, Lee WH, et al: miRTarBase update 2018: A resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 46:D296–D302. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Liu W and Wang X: Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol. 20(18)2019.PubMed/NCBI View Article : Google Scholar | |
|
Garcia DM, Baek D, Shin C, Bell GW, Grimson A and Bartel DP: Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Natu Struct Mol Biol. 18:1139–1146. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Escandón M, Lamelas L, Roces V, Guerrero-Sanchez VM, Meijón M and Valledor L: Protein interaction Networks: Functional and statistical approaches. Methods Mol Biol. 2139:21–56. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Ge SX, Jung D and Yao R: ShinyGO: A graphical gene-set enrichment tool for animals and plants. Bioinformatics. 36:2628–2629. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al: STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47:D607–D613. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Guo J, Zhou X, Cheng L and Gao X: Construction of a miRNA-mRNA network related to exosomes in metastatic hepatocellular carcinoma. Heliyon. 9(e15428)2023.PubMed/NCBI View Article : Google Scholar | |
|
Wei SY, Guo S, Feng B, Ning SW and Du XY: Identification of miRNA-mRNA network and immune-related gene signatures in IgA nephropathy by integrated bioinformatics analysis. BMC Nephrol. 22(392)2021.PubMed/NCBI View Article : Google Scholar | |
|
Morimatsu M, Yamashita E, Seno S, Sudo T, Kikuta J, Mizuno H, Okuzaki D, Motooka D and Ishii M: Migration arrest of chemoresistant leukemia cells mediated by MRTF-SRF pathway. Inflamm Regen. 40(15)2020.PubMed/NCBI View Article : Google Scholar | |
|
Li P, Li Y, Dai Y, Wang B, Li L, Jiang B, Wu P and Xu J: The LncRNA H19/miR-1-3p/CCL2 axis modulates lipopolysaccharide (LPS) stimulation-induced normal human astrocyte proliferation and activation. Cytokine. 131(155106)2020.PubMed/NCBI View Article : Google Scholar | |
|
Zhang H, Zhang Z, Gao L, Qiao Z, Yu M, Yu B and Yang T: miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9. Onco Targets Ther. 12:2149–2157. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Yang Y, Yang H, Lian X, Yang S, Shen H, Wu S, Wang X and Lyu G: Circulating microRNA: Myocardium-derived prenatal biomarker of ventricular septal defects. Front Genet. 13(899034)2022.PubMed/NCBI View Article : Google Scholar | |
|
Cowan C, Muraleedharan CK, O'Donnell JJ III, Singh PK, Lum H, Kumar A and Xu S: MicroRNA-146 inhibits thrombin-induced NF-κB activation and subsequent inflammatory responses in human retinal endothelial cells. Invest Ophthalmol Vis Sci. 55:4944–4951. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Xu M, Sun J, Yu Y, Pang Q, Lin X, Barakat M, Lei R and Xu J: TM4SF1 involves in miR-1-3p/miR-214-5p-mediated inhibition of the migration and proliferation in keloid by regulating AKT/ERK signaling. Life Sci. 254(117746)2020.PubMed/NCBI View Article : Google Scholar | |
|
Zhao Y, Tang X, Zhao Y, Yu Y and Liu S: Diagnostic significance of microRNA-1255b-5p in prostate cancer patients and its effect on cancer cell function. Bioengineered. 12:11451–11460. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Li Y, Bai W and Zhang J: MiR-200c-5p suppresses proliferation and metastasis of human hepatocellular carcinoma (HCC) via suppressing MAD2L1. Biomed Pharmacother. 92:1038–1044. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Al-Haidari A, Algaber A, Madhi R, Syk I and Thorlacius H: MiR-155-5p controls colon cancer cell migration via post-transcriptional regulation of Human Antigen R (HuR). Cancer Lett. 421:145–151. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Zhang Y and Ruan F: LncRNA LEF1-AS1 promotes ovarian cancer development through interacting with miR-1285-3p. Cancer Manag Res. 12:687–694. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wu Q, Zhong H, Jiao L, Wen Y, Zhou Y, Zhou J, Lu X, Song X and Ying B: MiR-124-3p inhibits the migration and invasion of Gastric cancer by targeting ITGB3. Pathol Res Pract. 216(152762)2020.PubMed/NCBI View Article : Google Scholar | |
|
Sathyanarayanan A, Chandrasekaran KS and Karunagaran D: microRNA-146a inhibits proliferation, migration and invasion of human cervical and colorectal cancer cells. Biochem Biophys Res Commun. 480:528–533. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Liu Q, Wang W, Yang X, Zhao D, Li F and Wang H: MicroRNA-146a inhibits cell migration and invasion by targeting RhoA in breast cancer. Oncol Rep. 36:189–196. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Shibayama Y, Kondo T, Ohya H, Fujisawa S, Teshima T and Iseki K: Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients. Oncol Rep. 33:2176–2182. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Li Y, Zhu X, Gu J, Hu H, Dong D, Yao J, Lin C and Fei J: Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis. Hematology. 15:215–221. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Liu X, Liao W, Peng H, Luo X, Luo Z, Jiang H and Xu L: miR-181a promotes G1/S transition and cell proliferation in pediatric acute myeloid leukemia by targeting ATM. J Cancer Res Clin Oncol. 142:77–87. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Duarte D, Amarteifio S, Ang H, Kong IY, Ruivo N, Pruessner G, Hawkins ED and Lo Celso C: Defining the in vivo characteristics of acute myeloid leukemia cells behavior by intravital imaging. Immunol Cell Biol. 97:229–235. 2019.PubMed/NCBI View Article : Google Scholar |
